Gurugram-based healthcare startup Oncare has raised ₹27 crore (US$2.96 million) in a Series A funding round led by Sky Impact Capital, with participation from Huddle Ventures, Lotus Herbal Group, Steerx, and Tremis Capital.
Oncare operates oncology departments within mid-sized, non-branded hospitals and aims to expand its footprint across India. The company claims it offers chemotherapy at approximately 40% lower costs than corporate hospitals—around ₹24,000–25,000 per session—and surgeries at 30–40% lower prices. Since launch, it declares it has served tens of thousands of patients.
The startup plans to deploy the fresh capital toward geographic expansion and scaling its network of cancer care centers, particularly in tertiary cities across Uttar Pradesh, Bihar, and West Bengal.
Key Highlights
- Oncare raises ₹27 crore in Series A to expand oncology network
- Claims chemotherapy costs 40% lower than corporate hospitals
- Tarobtains Tier 2 and Tier 3 cities to improve cancer care access
Its model is built on pooled procurement, combining drug orders across partner hospitals to reduce per-unit costs. This approach addresses a key challenge: many mid-sized hospitals purchase high-cost oncology drugs individually, limiting bargaining power and raising patient costs.
India’s National Cancer Grid previously nereceivediated drug procurement for 23 centers, achieving median savings of 82% versus maximum retail prices. Lower prices are critical, as studies reveal a standard early-stage HER2+ breast cancer regimen can cost nearly 10 years of average annual wages in India.
Also Read: Zeya Health Raises $575K to Scale AI Clinic Automation
By embedding specialist oncology services within existing hospitals, Oncare aims to reduce travel and accommodation burdens for patients outside major metros—potentially creating a scalable model for other complex medical services.
Leave a Reply